z-logo
open-access-imgOpen Access
PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin
Author(s) -
Hanke Nina,
Frechen Sebastian,
Moj Daniel,
Britz Hannah,
Eissing Thomas,
Wendl Thomas,
Lehr Thorsten
Publication year - 2018
Publication title -
cpt: pharmacometrics and systems pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 37
ISSN - 2163-8306
DOI - 10.1002/psp4.12343
Subject(s) - physiologically based pharmacokinetic modelling , pharmacology , pharmacokinetics , alfentanil , digoxin , itraconazole , cyp3a4 , midazolam , efavirenz , therapeutic drug monitoring , medicine , human immunodeficiency virus (hiv) , fentanyl , antifungal , antiretroviral therapy , cytochrome p450 , viral load , sedation , heart failure , family medicine , dermatology , metabolism
According to current US Food and Drug Administration ( FDA ) and European Medicines Agency ( EMA ) guidance documents, physiologically based pharmacokinetic ( PBPK ) modeling is a powerful tool to explore and quantitatively predict drug‐drug interactions ( DDI s) and may offer an alternative to dedicated clinical trials. This study provides whole‐body PBPK models of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin within the Open Systems Pharmacology ( OSP ) Suite. All models were built independently, coupled using reported interaction parameters, and mutually evaluated to verify their predictive performance by simulating published clinical DDI studies. In total, 112 studies were used for model development and 57 studies for DDI prediction. 93% of the predicted area under the plasma concentration‐time curve ( AUC ) ratios and 94% of the peak plasma concentration (C max ) ratios are within twofold of the observed values. This study lays a cornerstone for the qualification of the OSP platform with regard to reliable PBPK predictions of enzyme‐mediated and transporter‐mediated DDI s during model‐informed drug development. All presented models are provided open‐source and transparently documented.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here